Loading
A phase 3 trial testing Domvanalimab in non-small-cell lung cancer, active and no longer recruiting.
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC is a phase 3 interventional study registered as NCT05211895, led by AstraZeneca with Arcus Biosciences, and active but no longer recruiting on the registry. Official title: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab Plus Domvanalimab(AB154) in Participants With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease Has Not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy. Planned enrolment is 791 participants (actual). The study started in 2022-02-18 and primary completion is expected in 2026-08-10. No results have been posted on ClinicalTrials.gov.
Shares Domvanalimab, Non-small-cell lung cancer.
Shares Unresectable stage III non-small-cell lung cancer, AstraZeneca.
Shares Unresectable stage III non-small-cell lung cancer, AstraZeneca.
Shares Unresectable stage III non-small-cell lung cancer, AstraZeneca, Non-small-cell lung cancer.
Shares Unresectable stage III non-small-cell lung cancer, AstraZeneca, Non-small-cell lung cancer.
Shares Unresectable stage III non-small-cell lung cancer, AstraZeneca, Non-small-cell lung cancer.
Shares Domvanalimab, Non-small-cell lung cancer.
Shares Domvanalimab, Non-small-cell lung cancer.